default author photo

Daniel S. W. Tan

National Cancer Centre Singapore - Division of Medical Oncology

SCHOLARLY PAPERS

1

DOWNLOADS

21

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

A First-in-Human Phase 1/2 Dose-Escalation Study of Mak683 (Eed Inhibitor) in Patients with Advanced Malignancies

Number of pages: 21 Posted: 09 Oct 2024
Gustave Roussy - Drug Development Department (DITEP), Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, affiliation not provided to SSRN, The Chinese University of Hong Kong (CUHK), Shizuoka Cancer Center, University of Cologne, University of Toronto - Princess Margaret Cancer Centre, Sarah Cannon Research Institute, affiliation not provided to SSRN, National Cancer Centre Singapore - Division of Medical Oncology, Humanitas University - Department of Biomedical Sciences, affiliation not provided to SSRN, National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 21 (1,448,301)

Abstract:

Loading...

MAK683, EED, PRC2, DLBCL, ES, dose-escalation